Prestige BioPharma Pte Ltd
Prestige BioPharma is a Singapore-based biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics. Its lead program, HD201 Trastuzumab biosimilar, is under Phase 3 clinical development and will be filed with EMA and USFDA in 2019. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase 1 and an Adalimumab biosimilar (PBP1502) and an innovative anti-PAUF mAb (PBP1510) in preclinical stages.